Under the terms of the collaboration, both the companies will develop novel drug candidates against multiple targets across different therapeutic areas.
Initially, NovAliX will employ its protein biochemistry expertise in combination with its comprehensive biophysical technology platform.
NovAliX will also apply Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.
Furthermore, NovAliX will receive technology access fees as well as research funding payments.
The financial terms of the transaction have not been revealed.